BCR-ABL1/ABL reduction ratio superiority over EMR and halving time as a predictor for outcome in Egyptian chronic phase chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.

Citation:
Elbogdady, M., S. Shamaa, E. Azmy, T. Abozeid, M. AbdElmoety, and Z. Emara, "BCR-ABL1/ABL reduction ratio superiority over EMR and halving time as a predictor for outcome in Egyptian chronic phase chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.", 24th Congress of the European Hematology Association, June 2019: Abst. PB1927, Amsterdam, The Netherlands , HemaSphere 2019, 3 (S1), pp. 876, 2019.